| Bioactivity | Grisnilimab setaritox (WT1-RTA), is an antihuman T cell antibody (anti-CD7) conjugating with ricin A chain (RTA). RTA is a 30-kDa peptide capable of rapidly in activating ribosomal 60S subunits. Grisnilimab setaritox is cytotoxic to CEM (T-lymphoblastic leukemia) cells in vitro with an ID50 of 53 pM. Grisnilimab setaritox also improves leukemic meningitis model in rhesus monkeys[1]. |
| Invitro | Grisnilimab setaritox (2.5 μg/mL; 24 h) 对 T 淋巴白血病 CEM 细胞具有细胞毒性[1]。 |
| In Vivo | Grisnilimab setaritox (60 μg, 120 μg; 鞘内注射或静脉注射; 单剂量) 在恒河猴白血病性脑膜炎模型中，有抑制 T-ALL 脑膜白血病的潜力[1]。Grisnilimab setaritox (60 μg; 静脉注射; 每周 1 次共 6 周, 或每天 1 次共 7 天) 在恒河猴模型中，导致 CSF 粒细胞增多症和抗免疫毒素抗体[1]。 |
| Name | Grisnilimab setaritox |
| CAS | 2361013-29-6 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Hertler AA, et al. An immunotoxin for the treatment of T-acute lymphoblastic leukemic meningitis: studies in rhesus monkeys. Cancer Immunol Immunother. 1989;28(1):59-66. |